Case number 1:24-cv-00043
Heron Therapeutics, Inc. v. Mylan Pharmaceuticals Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Feb 2, 2024 | 15 | ANSWER to 1 Complaint ,Separate Defenses, and, COUNTERCLAIM against Heron Therapeutics, Inc. by Mylan Pharmaceuticals Inc..(Moore, David) (Entered: 02/02/2024) (30) |
| Feb 2, 2024 | 16 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Mylan Inc., Corporate Parent Viatris Inc. for Mylan Pharmaceuticals Inc. filed by Mylan Pharmaceuticals Inc.. (Moore, David) (Entered: 02/02/2024) (1) |
| Jan 26, 2024 | 12 | STIPULATION and [Proposed] Order to Consolidate and Extend Time by Heron Therapeutics, Inc.. (Tigan, Jeremy) (Entered: 01/26/2024) (2) |
| Jan 26, 2024 | 13 | Joint Letter to The Honorable William C. Bryson from Jeremy A. Tigan regarding Consolidation - re (12 in 1:24-cv-00043-WCB, 34 in 1:23-cv-01015-WCB) Stipulation. (Tigan, Jeremy) (Entered: 01/26/2024) (2) |
| Jan 26, 2024 | 14 | STIPULATION AND ORDER consolidating cases. Signed by Judge William C. Bryson on 1/26/2024. Associated Cases: 1:23-cv-01015-WCB, 1:24-cv-00043-WCB(gva) (Entered: 01/26/2024) (2) |
| Jan 26, 2024 | N/A | Case associated with lead case: Create association to 1:23-cv-01015-WCB. ALL FILINGS SHALL BE MADE IN THE LEADE CASE 1:23-cv-01015-WCB ONLY. (smg) (Entered: 01/29/2024) (0) |
| Jan 22, 2024 | N/A | Pro Hac Vice Attorney Christopher P. Hill,Mark Russell Sperling,Isaac S. Ashkenazi,Bruce M. Wexler for Heron Therapeutics, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (apk) (Entered: 01/22/2024) (0) |
| Jan 20, 2024 | 11 | ORAL ORDER: The parties are directed to advise the court by letter whether this case is suitable for consolidation with Heron Therapeutics, Inc. v. Mylan Pharmaceuticals Inc., No. 23-1015. The parties letters will be due for filing by January 26, 2024. Signed by Judge William C. Bryson on 1/20/2024. (gva) (Entered: 01/20/2024) (0) |
| Jan 18, 2024 | 8 | MOTION for Pro Hac Vice Appearance of Attorney Bruce M. Wexler, Isaac S. Ashkenazi, Christopher P. Hill, and Mark Russell Sperling - filed by Heron Therapeutics, Inc.. (Tigan, Jeremy) (Entered: 01/18/2024) (6) |
| Jan 18, 2024 | 9 | Pro Hac Vice Fee - Credit Card Payment received for Bruce M. Wexler, Isaac S. Ashkenazi, Christopher P. Hill, and Mark Russell Sperling. ( re 8 MOTION for Pro Hac Vice Appearance of Attorney Bruce M. Wexler, Isaac S. Ashkenazi, Christopher P. Hill, and Mark Russell Sperling )( Payment of $ 200, receipt number ADEDC-4317723).(Tigan, Jeremy) (Entered: 01/18/2024) (0) |
| Jan 18, 2024 | 10 | SO ORDERED, re 8 MOTION for Pro Hac Vice Appearance of Attorney Bruce M. Wexler, Isaac S. Ashkenazi, Christopher P. Hill, and Mark Russell Sperling filed by Heron Therapeutics, Inc. Signed by Judge William C. Bryson on 1/18/2024. (mpb) (Entered: 01/18/2024) (6) |
| Jan 17, 2024 | N/A | Case Assigned to Judge William C. Bryson of the United States Court of Appeals for the Federal Circuit, due to related cases. Please include the initials of the Judge (WCB) after the case number on all documents filed. (rjb) (Entered: 01/17/2024) (0) |
| Jan 12, 2024 | 7 | SUMMONS Returned Executed by Heron Therapeutics, Inc..Mylan Pharmaceuticals Inc. served on 1/12/2024, answer due 2/2/2024. (Tigan, Jeremy) (Entered: 01/12/2024) (2) |
| Jan 11, 2024 | 1 | COMPLAINT for ANDA/PATENT INFRINGEMENT filed against Mylan Pharmaceuticals Inc. ( Filing fee $ 405, receipt number ADEDC-4312941.) - filed by Heron Therapeutics, Inc.. (Attachments: # 1 Exhibit A-J, # 2 Civil Cover Sheet) (vfm) (Entered: 01/12/2024) (0) |
| Jan 11, 2024 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) (Entered: 01/12/2024) (3) |
| Jan 11, 2024 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/18/2023. Date of Expiration of Patent: 09/18/2035.Thirty Month Stay Deadline: 6/18/2026. (vfm) (Entered: 01/12/2024) (1) |
| Jan 11, 2024 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s): See Attached. (vfm) (Entered: 01/12/2024) (2) |
| Jan 11, 2024 | 5 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Heron Therapeutics, Inc.. (vfm) (Entered: 01/12/2024) (1) |
| Jan 11, 2024 | 6 | Summons Issued as to Mylan Pharmaceuticals Inc. on 1/11/2024. (vfm) (Entered: 01/12/2024) (2) |
